Pulchinenoside control MeCP2 expression in FLS from RA model rats.
- Author:
Cheng-Gui MIAO
;
Guo-Liang ZHOU
;
Mei-Song QIN
;
Jian-Zhong CHEN
;
Cheng-Feng LI
;
Hua-Qi HE
- Publication Type:Journal Article
- MeSH:
Animals;
Arthritis, Rheumatoid;
drug therapy;
genetics;
metabolism;
Disease Models, Animal;
Drugs, Chinese Herbal;
administration & dosage;
Fibroblasts;
drug effects;
metabolism;
Gene Expression Regulation;
drug effects;
Humans;
Male;
Methyl-CpG-Binding Protein 2;
genetics;
metabolism;
Rats;
Rats, Sprague-Dawley;
Synovial Membrane;
cytology;
drug effects;
metabolism;
Wnt Signaling Pathway;
drug effects;
beta Catenin;
genetics;
metabolism
- From:
China Journal of Chinese Materia Medica
2014;39(23):4664-4668
- CountryChina
- Language:Chinese
-
Abstract:
The role of pulchinenoside (PULC) in the regulation of MeCP2 expression was investigated in RA model rats. Adjuvant arthritis rats were used as RA model rats, and fibroblast-like synoviocytes (FLS) from the RA model rats were cultured. The effect of 100 mg x kg(-1) PULC gavage treatment on the MeCP2 expression and the effect of MeCP2 siRNA on the expression of SFRP2 and β-catenin were detected by real time qPCR and Western blotting. The role of PULC in the FLS proliferation was detected by MTT. The results showed that the MeCP2 expression was down-regulated, the SFRP2 expression was up-regulated and the FLS proliferation was inhibited in FLS after therapy. MeCP2 siRNA significantly inhibited the MeCP2 expression, up-regulated the SFRP2 expression and inhibited the β-catenin expression in FLS from RA model rats. PULC may increase the SFRP2 expression, inhibit the Wnt signaling and inhibit the FLS proliferation in FLS from the RA model rats by inhibiting the MeCP2 expression.
